Treatment of recalcitrant atopic dermatitis with Omalizumab

Article · February 2006with9 Reads
DOI: 10.1016/j.jaad.2005.09.030 · Source: PubMed
Atopic dermatitis is a common diagnosis that presents a therapeutic challenge. Although multiple therapeutic modalities exist, there is no single monotherapy that has proven exceptional in ameliorating the symptoms of this disease. Current topical and systemic therapeutic options offer benefit but carry varying degrees of adverse effects that often limit their application. We present 3 patients with severe, recalcitrant atopic dermatitis successfully treated with omalizumab.
  • ...Eczema is a chronic inflammatory skin disorder with a lifetime risk of up to 22% of children by the age of 12–14 years. The available literature suggests that anti-immunoglobulin E (anti-IgE) may be of benefit in the treatment of eczema from at least the age of 7 years[1][2][3][4]. Studies and case reports to date have had small numbers of participants, have not been randomised or placebo controlled, or have included a heterogenous mix of participants of different ages. ...
  • ...Due to the frequent finding of elevated IgE levels in patients with atopic dermatitis (AD), it was postulated that reducing IgE levels in peripheral blood and skin by use of agents such as Omalizumab, may have beneficial effects in AD.[10]There have been mixed reports about the efficacy of Omalizumab in treatment of AD, with Lane et al.[11]reporting significant improvement in three patients, Vigo et al.[12]showed improvements in five out of seven patients, while Krathen and Hsu[13]described three cases of severe AD in adults who did not respond well to Omalizumab. Based on these reports it is currently difficult to make recommendations about use of Omalizumab in cases of AD, and more studies are needed. ...
  • ...In 2005, Krathen and Hsu observed no response to omalizumab in three patients with severe AD when administered for 4 months [73]. However, same year, Lane et al. reported three patients with severe, recalcitrant atopic dermatitis successfully treated with omalizumab [74]. In 2006, Vigo et al. reported a significant improvement in the symptoms of all 7 AD patients treated who received omalizumab for their persistent asthma [75]. ...
March 2008 · The Journal of allergy and clinical immunology · Impact Factor: 11.48
    November 2013 · Journal of the American Academy of Dermatology · Impact Factor: 4.45
      June 2008 · Current Allergy and Asthma Reports · Impact Factor: 2.77
        October 2012 · Clinical and Experimental Dermatology · Impact Factor: 1.09
          Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease affecting > 10% of children and 1-3% of adults, and can cause significant morbidity. The incidence of AD seems to be increasing. Omalizumab, a monoclonal antibody, has recently been suggested as a potential new systemic treatment for patients with recalcitrant AD with elevated IgE levels, based on its efficacy in... [Show full abstract]
          Discover more